• 1
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 6166.
  • 2
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210218.
  • 3
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640650.
  • 4
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 26952701.
  • 5
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 6
    Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003; 21: 41754183.
  • 7
    Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26: 955969.
  • 8
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 22922299.
  • 9
    Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005; 14: 142150.
  • 10
    Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15: 422430.
  • 11
    Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog—methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006; 95: 125129.
  • 12
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 13871397.
  • 13
    Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005; 23: 80258032.
  • 14
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612619.
  • 15
    Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001; 19: 812820.
  • 16
    Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005; 104: 24992507.
  • 17
    Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006; 17: 415423.
  • 18
    Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828834.
  • 19
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967982.
  • 20
    Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005; 59: 6070.
  • 21
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005; 104: 22222233.
  • 22
    O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005; 5: 439446.
  • 23
    Harting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. WMS-R. Wechsler Gedachtnistest-Revidierte Fassung [in German]. 2nd ed. Bern: Huber, 2004.
  • 24
    Tewes U. HAWIE-R. Hamburg-Wechsler Intelligen Test for Erwachsene, revision 1991, 2nd ed [in German]. Bern: Huber; 1994.
  • 25
    Brickenkamp R. Test D2. Aufmerksamkeits-Belastungs-Test, 9th ed [in German]. Gottingen: Hogrefe; 2002.
  • 26
    Reitan RM. Trail Making Test. ed. 2. Tucson, Ariz: Reitan Neuropsychology Laboratory; 1992.
  • 27
    Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. Trail Making Test: normative values from 287 normal adult controls. Ital J Neurol Sci. 1996; 17: 305309.
  • 28
    Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19: 203214.
  • 29
    Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
  • 30
    Aschenbrenner S, Tucha O, Lange KW. RWT. Regensburger Wortflussigkeits-Test [in German]. Gottingen: Hogrefe; 2000.
  • 31
    Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Balingen: Spitta; 1999.
  • 32
    Suslow T, Arolt V, Junghanns K. Differentielle Validitat des Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA): konkurrente Validierungsergebnisse bei schizophrenen und depressiven Patienten [in German]. Z Klin Psychol Psychiatr Psychother. 1998; 46: 152165.
  • 33
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 34
    Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
  • 35
    Herrmann C, Buss U, Snaith RP HADS-D. Hospital Anxiety and Depression Scale. German Version, 1st ed. Berne: Huber; 1995.
  • 36
    Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59: 1219.
  • 37
    De Monte VE, Geffen GM, Kwapil K. Test-retest reliability and practice effects of a rapid screen of mild traumatic brain injury. J Clin Exp Neuropsychol. 2005; 27: 624632.
  • 38
    McCaffrey RJ, Duff K, Westervelt HJ. Practitioner's Guide to Evaluating Change With Neuropsychological Assessment Instruments. New York, NY: Kluwer Academic/Plenum Publishers; 2000.
  • 39
    McCaffrey RJ, Duff K, Westervelt HJ. Practitioner's Guide to Evaluating Change With Intellectual Assessment Instruments. New York, NY: Kluwer Academic/Plenum Publishers; 2000.
  • 40
    Youngjohn JR, Larrabee GJ, Crook TH. Test-retest reliability of computerized, everyday memory measures and traditional memory tests. Clin Neuropsychol. 1992; 6: 276286.
  • 41
    Bruggemans EF, Van de Vijver FJ, Huysmans HA. Assessment of cognitive deterioration in individual patients following cardiac surgery: correcting for measurement error and practice effects. J Clin Exp Neuropsychol. 1997; 19: 543559.
  • 42
    Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005; 14: 7078.
  • 43
    Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. “Chemobrain” in breast carcinoma? A prologue. Cancer. 2004; 101: 466475.
  • 44
    Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996; 74: 16741679.
  • 45
    Gurevich M, Devins GM, Rodin GM. Stress response syndromes and cancer: conceptual and assessment issues. Psychosomatics. 2002; 43: 259281.
  • 46
    Horner MD, Hamner MB. Neurocognitive functioning in posttraumatic stress disorder. Neuropsychol Rev. 2002; 12: 1530.